Acquired cholesteatoma: Summary of the cascade of molecular events

Journal of Laryngology and Otology

Volumn 127, Issue 6, 2013, Pages 542-549

  Louw, L ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Biochemistry; Cholesteatoma; Ear; Enzymes; Inflammation; Middle; Pathology

Indexed keywords

ARACHIDONIC ACID; ESTRADIOL; LINOLEIC ACID; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BIOFILM; BONE EROSION; CELL PROLIFERATION; CHOLESTEATOMA; CHRONIC INFLAMMATION; CHRONIC OTITIS MEDIA; CYTOKINE PRODUCTION; HEARING IMPAIRMENT; HUMAN; HYPOXEMIA; LIPID MEMBRANE; NONHUMAN; OXIDATIVE STRESS; TUMOR GROWTH;

APOPTOSIS; CELL PROLIFERATION; CHOLESTEATOMA, MIDDLE EAR; EAR, MIDDLE; FATTY ACIDS; HUMANS; INFLAMMATION; LIPID METABOLISM;

EID: 84878770460     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215113000601     Document Type: Article

References (67)

1. Louw L. Acquired cholesteatoma pathogenesis: stepwise explanations. J Laryngol Otol 2010;124:587-93
2. Olszewska E, Wagner M, Bernal-Sprekelson M, Ebmeyer J, Dazert S, Hildmann H et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004;261:6-24
3. Tos M. Manual of Middle Ear Surgery. New York: Thieme, 1993
4. Seibert JW, Danner CJ. Eustachian tube function and the middle ear. Otolaryngol Clin North Am 2006;39:1221-35
5. Chole RA, Sudhoff HH. Chronic otitis media, mastoiditis and petrositis. In Cummings Otolaryngology: Head and Neck Surgery, 4th edn: Mosby Elsevier, 2005;4:2988-3003
6. Sudhoff H, Tos M. Pathogenesis of sinus cholesteatoma. Eur Arch Otorhinolaryngol 2007;264:137-43
7. Mishiro Y, Sakagami M, Kitahara T, Kondoh K, Okumura S. The investigation of the recurrence rate of cholesteatoma using Kaplein-Meier survival analysis. Otol Neurotol 2008;29:803-6
8. Mustafa A, Heta A, Kastrai B, Dreshaj SH. Complications of chronic otitis media with cholesteatoma during a 10-year period in Kosovo. Eur Arch Otorhinolaryngol 2008;265:1477-82
9. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol Head Neck Surg 2002;128: 1129-33
10. Post JC, Hiller NL, Nistico L, Stoodley P, Ehrlich GD. The role of biofilms in otolaryngologic infections: update 2007. Curr Opin Otolaryngol Head Neck Surg 2007;15:347-51
11. Macassey E, Dawes P. Biofilms and their role in otorhinolaryngological disease. J Laryngol Otol 2008;122:1273-8
12. Wang E, Jung J, Nason R, Pashia M, Chole R. Characterization of otopathogenic Pseudomonas aeruginosa: a biofilm phenotype. Arch Otolaryngol Head Neck Surg 2005;131:983-9
13. Junh SK, Jung M-K, Hoffman MD, Drew BR, Preciado DA, Sausen NJ et al. The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol 2008;1:117-38
14. Peek FAW, Huisman M, Berckmans RJ, Sturk A, van Loon J, Grote JJ. Lipopolysaccharide concentration and bone resorption in cholesteatoma. Otol Neurotol 2003;24:709-13
15. Dornelles C, da Costa SS, Meurer L, Schweiger C. Correlation of cholesteatomas perimatrix thickness with patient's age. Rev Bras J Otorrinolaringol 2005;6:792-7
16. Nagai T, Suganuma T, Ide S, Shimoda H, Kato S. Confirmation of mucin in lymphatic vessels of acquired cholesteatoma. Eur Arch Otorhinolaryngol 2006;263:361-4
17. Sudhoff H, Dazert S, Gonzales AM, Borkowski G, Park SY, Baird A et al. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma. Am J Otol 2000;21:793-8
18. Adunka O, Gstoettner W, Knecht R, Kiener AC. Expression of hypoxia inducible factor 1 alpha and Von Hippel Lindau protein in human middle ear cholesteatoma. Laryngoscope 2003;113: 1210-15
19. Olszewska E, Chodynicki S, Chyczewski L. Apoptosis in the pathogenesis of cholesteatoma in adults. Eur Arch Otorhinolaryngol 2006;263:409-13
20. Alves AL, Pereira CSB, Carvalho M de FP, Fregnani JHTG, Ribeiro FQ. EGFR expression in acquired middle ear cholesteatoma in children and adults. Eur J Pediatr 2012;171:307-10
21. Barbara M, Raffa S, Mure C, Manni V, Ronchetti F, Monini S et al. Keratinocyte growth factor receptor (KGF-R) in cholesteatoma tissue. Acta Otolaryngol 2008;128:360-4
22. Yamamoto-Fukuda T, Takahasi H, Koji T. Expression of keratinocyte growth factor and its receptor in a middle ear cavity problem. Int J Pediatr Otorhinolaryngol 2012;76:76-81
23. Jin BJ, Min HJ, Jeong JH, Park CW, Lee SH. Expression of EGFR and microvessel density in middle ear cholesteatoma. Clin Exp Otorhinolaryngol 2011;4:67-71
24. Macias MP, Gerkin RD, Macias JD. Increased amphiregulin expression as a biomarker of cholesteatoma activity. Laryngoscope 2010;120:2258-63
25. Kucczkowski J, Pawelczyk T, Bakowska A, Narozny W, Mikaszewski B. Expression of patterns of Ki-67 and telomerase activity in middle ear cholesteatoma. Otol Neurotol 2007;28: 204-7
26. Olszewska E, Lautermann J, Koc C, Schwaab M, Dazert S, Hildmann H et al. Cytokeratin expression pattern in congenital and acquired pediatric cholesteatoma. Eur Arch Otorhinolaryngol 2005;262:731-6
27. Olszewska E, Sudhoff H. Comparative cytokeratin distribution patterns in cholesteatoma epithelium. Histol Histopathol 2007; 22:37-42
28. Park HR, Min SK, Min K, Jun SY, Seo J, Kim HJ. Increased expression of p63 and survivin in cholesteatomas. Acta Otolaryngol 2009;129:268-72
29. Kuczkowski J, Bakowska J, Pawelczyk T, Narozny W, Mikaszewski B. Cell cycle inhibitory protein p27 in human middle ear cholesteatoma. ORL J Otorhinolaryngol Relat Spec 2006;68:296-301
30. Sakamoto T, Kondo K, Yamasodba T, Suzuki M, Sugasawa M, Kaga K. Over-expression of ErbB-2 protein in middle ear cholesteatomas. Laryngoscope 2004;114:1988-91
31. Osturk K, Yildirim MS, Ascar H, Cenik Z, Keles B. Evaluation of c-myc status in primary acquired cholesteatoma by using fluorescence in situ hybridization techniques. Otol Neurotol 2006; 27:588-91
32. Motamed M, Powe D, Kendall C, Birchall JP, Banerjee AR. p53 Expression and keratinocyte hyperproliferation in middle ear cholesteatoma. Clin Otolaryngol Allied Sci 2002;27:505-8
33. Huang CC, Chen CT, Huang TS, Shinoda H. Mediation of signal transduction in keratinocytes of human middle ear cholesteatoma by ras protein. Eur Arch Otorhinolaryngol 1996;253:385-9
34. Miyao M, Shinoda H, Takahashi S. Caspase-3, caspase-8 and nuclear factor-kappa beta expression in human cholesteatoma. Otol Neurotol 2006;27:8-1
35. Jung MH, Lee JH, Cho JG, Jung HH, Hwang SJ, Chae SW. Expressions of caspase-14 in human middle ear cholesteatoma. Laryngoscope 2008;118:1047-50
36. Huisman MA, De Heer E, Grote JJ. Terminal differentiation and mitogen-Activated protein kinase signaling in human cholesteatoma epithelium. Otol Neurotol 2006;27:422-6
37. Huisman MA, De Heer E, Grote JJ. Survival signaling and terminal differentiation in cholesteatoma epithelium. Acta Otolaryngol 2007;127:424-9
38. Niam R, Chang RC, Sadick H, Bayerl C, Bran G, Hormann K. Effect of vascular endothelial growth factor on fibroblasts from external auditory canal cholesteatoma. Arch Med Res 2005;36: 518-23
39. Morales SD, Penido N de O, da Silva NID, Stavale JN, Guilherme A, Fukuda Y. Matrix metalloproteinase 2: an important genetic marker for cholesteatomas. Braz J Otorhinolaryngol 2007;73:51-7
40. Song JJ, Chae SW, Woo JS, Lee HM, Jung HH, Hwang SJ. Differential expression of human beta defensin 2 and human beta defensin 3 in human middle ear cholesteatoma. Ann Otol Rhinol Laryngol 2007;116:235-40
41. Hussein MRA, Sayed RM, Abu-Dief EE. Immune cell profile in invasive cholesteatomas: preliminary findings. Exp Mol Pathol 2010;88:316-23
42. Huisman MA, de Heer E, Dijke PT, Grote JJ. Transforming growth factor beta and wound healing in human cholesteatoma. Laryngoscope 2007;118:94-8
43. Jung JY, Chole RA. Bone resorption in chronic otitis media: the role of the osteoclast. ORL J Otorhinolaryngol Relat Spec 2002; 64:95-107
44. Olszweska E, Borzym-Kluczyk M, Olszweska S, Rogowski M, Zwierz K. Hexosaminidase as a new potential marker for middle ear cholesteatoma. Clin Biochem 2006;39:1088-90
45. Vitale RF, Ribeiro F de AQ. The role of tumor necrosis factoralpha in bone resorption present in middle ear cholesteatoma. Bras J Otorrinolaringol 2007;73:123-7
46. Yuan J, Akiyama M, Nakahama K-I, Sato T, Uematsu H, Morita I. The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro. Prostaglandins Other Lipid Mediat 2010;92:85-90
47. Byun JY, Yune TY, Lee JY, Yeo SG, Park MS. Expression of CYLD and NF-κB in human cholesteatoma epithelium. Mediators Inflamm 2010;2010:796315. Epub 2010 Apr 21
48. Iino Y, Toriyama M, Ogawa H, Kawakami M. Cholesteatoma debris as an activator of human monocytes. Acta Otolaryngol (Stockh) 1990;110:410-15
49. Nason R, Jung JY, Chole RA. Lipopolysaccharide-induced osteoclastogenesis from mononuclear precursors: a mechanism for osteolysis in chronic otitis. J Assoc Res Otolaryngol 2009; 10:151-60
50. Hellstrom S, Eriksson PQ, Yoon YJ, Johansson U. Interactions between the middle ear and the inner ear: bacterial products. Ann N Y Acad Sci 1997;830:110-19
51. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21
52. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser MJ. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84
53. Eskiizmir G, Yuceturk AV, Onur E, Var A, Temiz P. The imbalance of enzymatic antioxidants in cholesteatoma. Acta Otolaryngol 2009;129:1187-91
54. Online textbook of bacteriology. In: http://textbookofbacteriology. net [30 January 2012]
55. Celebi O, Paksoy M, Aydin S, Sanh A, Tasdemir O, Gull AE. Myeloperoxydase activity in the pathogenesis of cholesteatoma. Indian J Otolaryngol Head Neck Surg 2010;62:32-5
56. Horrobin DF. Medical uses of essential fatty acids. Vet Dermatol 1994;4:161-6
57. Das UN. Essential fatty acids: a review. Curr Pharm Biotechnol 2006;7:467-82
58. Shah US, Dhir R, Golli SM, Chandran UR, Lewis D, Acquafondata M et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 2006;37:401-9
59. Martinasso G, Oraldi G, Trombetta A, Maggiora M, Bertetto M. Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Res 2007;2007:93416
60. Hwang SJ, Kang HJ, Song JJ, Kang JS,Woo JS, Chae SW et al. Up-regulation of peroxidase proliferator-Activated receptor gamma in cholesteatoma. Laryngoscope 2006;116:58-61
61. Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 2005;338:668-76
62. Khan M, Contreras M, Sing I. Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes. J Endotoxin Res 2000;6:41-50
63. Knowles HJ, Cleton-Jansen A-M, Korsching E, Athanasou NA. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J 2010;24:4648-59
64. O'Shea M, Bassagaya-Riera J, Mohede IC. Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 2004;79: 1199S-1206S
65. Aggarwal BB. Nuclear factor-kappa B: a transcription factor for all seasons. Expert Opin Ther Targets 2007;11:109-10
66. Jung JY, Lin AC, Ramos LM, Faddis BT, Chole RA. Nitric oxide synthase I mediates osteoclast activity in vitro and in vivo. J Cell Biochem 2003;89:613-21
67. Deon M, Garcia MP, Sitta A, Barschak AG, Coelho M, Graziela O et al. Hexacosanoic acid and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's effect. Metab Brain Dis 2008;23:43-9